ReportsnReports added a new report on The Biomarker Potential of Type I IFN Gene Signature in Lupus report that delivers the clean elaborated structure of the Report comprising each and every business-related information of the market at a global level. The in-depth study on the current state which focuses on the major drivers and restraints for the key players. Biomarker Potential of Type I IFN Gene Signature in Lupus Industry research report provides granular analysis of the market share, segmentation, revenue forecasts, geographic regions of the market and analytical tools such as SWOT analysis to generate a whole set of trade based studies regarding the Biomarker Potential of Type I IFN Gene Signature in Lupus.
Get FREE PDF Sample of the report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1732651
The briefing includes analysis of KOL opinion on the following topic areas –
– Awareness of biomarkers and predictors of disease activity in lupus
– Usefulness of the type I IFN signature test to identify patients who are most likely to respond to IFN-targeting therapies
– Impact of availability of a biomarker on willingness to prescribe a therapy
– Implementing a potential IFN biomarker test in clinical practice
– Willingness to prescribe anifrolumab to patients who do not display the interferon biomarker
– Barriers to using IFN signature test to stratify patients in clinical practice
– Impact of data suggesting that high IFN? gene expression is closely associated with SLE on opinion of anifrolumabs efficacy
– Impact of data suggesting that high IFN? gene expression is more closely associated with LN than IFN? on opinion of anifrolumabs efficacy
Key Highlights of this Report-
– Majority of KOLs use complement & anti-DNA to monitor disease activity in clinical practice, while most are aware of the type I IFN signature test
– Most KOLs flagged that the type I IFN signature test will be useful to stratify patients most likely to respond to type I IFN-targeting therapies
– Most KOLs agreed that the availability of a biomarker would strongly influence their willingness to prescribe a therapy such as anifrolumab.
Scope of this Report-
– The insight briefing is based on Sociable Pharmas analysis of primary research with our lupus key opinion leaders (KOLs)
– In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based
– Interviews performed in December 2017
– KOL data is analyzed to produce: Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma’s analysts.
Reasons to buy this Report-
– Combines Qualitative & semi-quantitative insight from key opinion leaders on “Biomarker Potential of Type I IFN Gene Signature in Lupus”
– Includes insight & recommendations from our disease-specific healthcare analysts
– Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
– Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Get FLAT 20% Discount on this Report @ https://www.reportsnreports.com/purchase.aspx?name=1732651
Table of Contents in this Report-
Research Panel Composition
Results & Implications